pSivida Corp. Stock Update – Up 3.15%

    Author Samara MalkinPosted on Categories Drug Manufacturers, Health, NASDAQTags , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
    pSivida Corp.

    pSivida Corp. (NASDAQ:$PSDV) stock is currently on the up and up.

    The stock finished Tuesday’s session 3.15% higher at $1.31, with a total trading volume of 570,811 shares. This means that the stock has risen 11.97% over the past three months. Furthermore, pSivida shares are actually trading above their 50-day moving average by 6.87%. Their Relative Strength Index (RSI) is sitting at 57.93.

    A Buy rating has been initiated for pSivida stock by the research firm Laidlaw, setting a target price of $5 per share.

    pSivida develops sustained-released drug-delivery products that are aimed at treating chronic eye diseases.

    Featured Image: twitter

    Author Samara Malkin
    About the author: Samara graduated from Simon Fraser University with a BA in English, minoring in Publishing and Creative Writing. One day she hopes to publish her very own novel, but in the meantime, she contents herself with blogging and editing. She currently specializes in writing financial news and analysis, as well as cryptocurrency news and information.